Clinical trialNCT00617669CompletedPhase 3Interventional

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

SponsorAstraZenecaEnrollment1,494Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Judd W Moul, MD, FACS
Duke University
Principal Investigator
clinicaltrials.gov ↗
Karim Fizazi, MD, PhD
Gustave Roussy, Cancer Campus, Grand Paris
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

147 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Bahía Blanca, Buenos Aires, Argentina
Research Site
Buenos Aires, Buenos Aires, Argentina
Research Site
Santa Fe, Santa Fe Province, Argentina

Australia

Research Site
Darlinghurst, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Wollongong, New South Wales, Australia
Research Site
Redcliffe, Queensland, Australia
Research Site
Ashford, South Australia, Australia
Research Site
Footscray, Victoria, Australia
Research Site
Wodonga, Victoria, Australia
Research Site
Perth, Western Australia, Australia
Research Site
Subiaco, Western Australia, Australia

Brazil

Research Site
Fortaleza, Ceara/ LA, Brazil
Research Site
Goiânia, Goias/ LA, Brazil
Research Site
Goiânia, Goiás, Brazil
Research Site
Belo Horizonte, Minas GERMANYais, Brazil
Research Site
Curitiba, Parana/ Brazil, Brazil
Research Site
Londrina, Paraná, Brazil
Research Site
PORTUGALto Alegre, Rio Grande Do Sul/ LA, Brazil
Research Site
Rio de Janeiro, Rio de Janeiro, Brazil
Research Site
Ribeirão Preto, Sao Paulo/ LA, Brazil
Research Site
Santo André, São Paulo, Brazil
Research Site
São Paulo, São Paulo, Brazil

Canada

Research Site
Winnipeg, Manitoba, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada

Czechia

Research Site
Olomouc, Czech Republic, Czechia
Research Site
Prague, Czech Republic, Czechia
Research Site
Ústí nad Labem, Czech Republic, Czechia
Research Site
Brno, Czechoslovakia Republic, Czechia
Research Site
Jablonec nad Nisou, Czechia
Research Site
Kroměříž, Czechia
Research Site
Prague, Czechia

Finland

Research Site
Helsinki, Finland, Finland
Research Site
Joensuu, Finland
Research Site
Seinäjoki, Finland

France

Research Site
La Roche-sur-Yon, FRANCEnce, France

107 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →PlaceboZibotentan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2008
Primary completion: 31 May 2011
Completion: 31 Jul 2011
Last update posted: 10 Sept 2012
Registered enrollment: 1,494
Registry id: NCT00617669

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.